摘要
肝细胞癌(hepatocellular carcinoma,HCC)是我国最常见的肝脏恶性肿瘤,严重威胁我国人民的生命和健康。目前,晚期HCC的治疗是以靶向和免疫治疗为主的系统性治疗,如何选择多靶点的抑制剂和合适的免疫治疗方案是当前研究的一大热点。随着各种基因测序技术的不断发展,探索靶向治疗和免疫治疗的生物学标志物,可精准地选择获益人群,预测药物疗效和疾病预后。本文将就HCC靶向和免疫治疗中疗效预测相关的生物学标志物研究进展进行综述。
Hepatocellular carcinoma(HCC) is the most common malignant liver tumor in China, which is seriously threating the life and health of our people. At present, molecular targeted therapy and immunotherapy are the mainly systematic treatment for advanced HCC. How to choose multi-targeted inhibitor and appropriate immunotherapy has become a research hotspot nowadays. With the continuous development of various sequencing technology, exploring the biomarkers of molecular targeted therapy and immunotherapy can precise select the benefcial population as well as predict drugs effcacy and disease prognosis. In this paper, we will review the advances of biomarker for effcacy prediction in targeted therapy and immunotherapy of hepatocellular carcinoma.
作者
何健
陈晓明
He Jian;Chen Xiaoming(Department of Interventional Radiology,Cancer Center/Guangdong General Hospital/Guangdong Academy of Medical Sciences,Guangzhou 510080,Guangdong,China;Medical College of Shantou University,Shantou 515041,Guangdong,China)
出处
《肝癌电子杂志》
2020年第3期39-42,共4页
Electronic Journal of Liver Tumor
